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The human microbiome has become a recognized factor in promoting and maintaining health. We
outline opportunities in interdisciplinary research, analytical rigor, standardization, and policy
development for this relatively new and rapidly developing field. Advances in these aspects of the
research community may in turn advance our understanding of human microbiome biology.
It is now widely recognized that disturbances in our normal microbial populations may be
linked to acute infections such as Clostridium difficile and to chronic diseases such as heart
disease, cancer, obesity, and autoimmune disorders (Clemente et al., 2012). This has
prompted substantial interest in the microbiome from both basic and clinical perspectives.
Although our genome is relatively static throughout life, each of our microbial communities
changes profoundly from infancy through adulthood, continuing to adapt through ongoing
exposures to diet, drugs and environment. Understanding the microbiome and its dynamic
nature may be critical for diagnostics and, eventually, interventions based on the
microbiome itself. However, several important challenges limit the ability of researchers to
enter the microbiome field and/or conduct research most effectively.

NIH-PA Author Manuscript

FUNDAMENTAL CHALLENGES
Many microbiome studies to date have focused on finding patterns, and moving towards
mechanism remains a major challenge. Once the “natural history” is better characterized
(research to date has focused on a few locations in the Western world leaving much to
described), the next step is to test for causality: when cases and controls differ, does the
microbiome cause the phenotypic change, does the phenotype drive a change in the
microbiome, or are there feedback loops between the two? Determining which factors in a
complex ecosystem are most associated with important differences is necessary for the
development of diagnostic or therapeutic strategies. For example, is the species membership,
gene functional profile, transcript or protein expression, metabolite profile, or a combination
thereof indicated in a particular condition? In this context, study designs that allow causal
inference, such as prospective longitudinal studies and randomized, controlled experimental
designs are crucial.

NIH-PA Author Manuscript

Current microbiome studies tend to take either top--down or bottom--up perspectives. The
former constitutes ecological or systems--level investigations of entire microbial
communities, while the latter focus on mechanistic examinations of the effects of individual
microbes, genes, or metabolites. For example, observations of whole--community changes
associated with obesity are now quite robust (Ley et al., 2005). The latter focuses on a more
detailed level, where several representative studies have been very successful in identifying
microbial effects in drug responses, such as the role of specific strains of the gut
Actinobacterium Eggerthella lenta in inactivating the cardiac glycoside drug digoxin
(Haiser et al., 2013) and of p-cresol production by certain gut bacteria interfering with host
detoxification of acetaminophen (Clayton et al., 2009). The dynamic nature of the
microbiome thus requires scientific approaches that incorporate aspects both of genetics and
of functional molecular studies into the experimental design. For example, integration of
ecology with molecular mechanism has identified gut microbial metabolism as a potential
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impediment in the use of therapeutic food for treatment of severe malnutrition in Malawi
(Smith et al., 2013), for example. Connecting top--down and bottom--up strategies to
determine specific mechanism as well as patterns of association is thus a key goal for the
field moving forward.

ASSAYING AND UNDERSTANDING THE MICROBIOME
Studies of the microbiome share, and in some cases magnify, hurdles common to many
current ‘omics fields. The cost of sequencing is dropping much faster than the cost of
analysis, creating a bottleneck in computation. Improved algorithms, increased personnel
trained in analysis of microbiome data, and access to free or inexpensive computing power
such as cloud-based resources would all help. Other technical challenges are unique to the
study of microbial communities. For example, because of the remarkable variation in the
microbiome between body sites, ages, locations, lifestyles, diets, and host genetics, our
definitions of “baseline” must continue to be expanded to survey the worldwide microbiome
in health and its perturbations in disease. This is true for all microbial components: viruses,
phage, eukaryotes, and archaea, as well as bacteria.

NIH-PA Author Manuscript
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Neither the data generation platforms nor the analysis methods used with the microbiome
have yet reached the level of refinement necessary for translational applications and
systematic meta--analyses, as has been achieved in other ‘omics areas such as gene
expression or genetics over many years of study. Unfortunately, there are not as yet uniform
standards for how data are deposited and how experiments are described. Data centralization
efforts such as the NCBI Short Read Archive (SRA), database of Genotypes and Phenotypes
(dbGaP), and BioSample must balance extremely broad accessibility - being all things to all
people - with the practical concerns necessary to easily deposit and retrieve individual
studies’ files. The diversity and lack of standards in human microbiome research has
resulted in little consistency in how data are deposited in these repositories, and many
incompatible file formats and conventions are currently in use. Consequently, it is very
difficult to reconcile data from different studies, even when the same phenotypes are
available. At the level of sequences deposited within these resources, field--specific
considerations such as barcoding and primers are not a part of the overall repository design
and may not be described well in metadata, leading to considerable challenges in
interpretation. The dataset resulting from the Human Microbiome Project (HMP) is one of
the largest such examples to date, where the automated deposition pipelines of multiple
sequencing centers resulted in a variety of files, some from re-sequencing of the same
sample and some containing as few as a single read after human read filtering (Human
Microbiome Project Consortium, 2012). For scientists who want to use such data products
for downstream research, even large datasets from individual projects thus pose a major data
integration challenge.
The microbiome of each subject exists in a demographic, environmental and clinical
context; the more precise the definition of clinical phenotypes and natural history, the
greater the analytic potential, particular in comparisons between studies. Comparison of data
and metadata between human microbiome studies is also susceptible to batch effects (where
samples processed at the same time appear to be different due to technical variation) and
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other technical challenges. Precise descriptions of phenotype, reproducible study designs,
and standardizing sampling techniques are thus important for assessing variability due to
technical effects, sampling bias, and other factors.
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Standardization of phenotype and sample processing is of critical importance, but the
development of controlled vocabularies (and tools to applying controlled vocabularies) is
not complete. One ontology used with the microbiome, EnvO, was originally developed for
environmental microbial communities and only partially resolves these problems
(Hirschman et al., 2008); synonyms or near- synonyms are common, such as “stool”,
“feces”, “faeces”, “gut”, etc. Likewise the gut has been annotated as a “Moist Tropical
Environment” in some datasets, but this is likely not the intended biome description.
Documentation supporting the use of the MIxS standard for the human microbiome
community and improved user interfaces for tools that allow annotation and deposition of
standards--compliant data could resolve a major bottleneck in current studies (Yilmaz et al.,
2011). Similarly, the PhenX project, which identifies a common set of phenotype variables
that are useful across many studies (Pan et al., 2012), provides a model for how microbiome
metadata could be annotated. Adherence to the PhenX standard and to obtaining BioSample
identifiers that are stable across multiple analyses of the same specimen will be especially
useful for complex multi’omic studies (Barrett et al., 2012), as well as for systematic meta-analysis of datasets where statistical power is limited due to small population sizes in
individual studies. This is especially important if microbiome data are to become more
rapidly applicable in clinical settings and in large--scale epidemiological studies.

HUMAN STUDIES ISSUES AND POTENTIAL SOLUTIONS
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Particularly in the United States, many opportunities exist to streamline microbiome
research efforts among institutions, at the national level, and for international collaborations.
For example, there are significant duplications of effort and inconsistencies resulting as
individual microbiome researchers consult with their local IRBs (Institutional Review
Boards) or other ethics committees, in part because microbiome studies are so new and do
not exactly fit the model of either human genetics or microbiological research. This is
particularly true for fecal microbiota transplantation, which has been increasingly
implemented into clinical practice with neither clear regulatory guidelines nor a transparent
facilitation of the associated research opportunities for making causal connections between
the microbiota and host physiology. Efforts initiated by the NIH’s Clinical and Translational
Science Award program, such as IRBShare, may be particularly applicable to the
microbiome to increase communication and sharing of best practices between IRBs in multisite studies. Registries designed to simplify recruiting clinical research volunteers are now
common and provide the added benefit of linking diverse projects across a national research
network (Richesson and Vehik, 2010). As a research community, we should consider
systems such as these to streamline subject recruitment, because they have been shown to
increase study enrollment and lower costs. Methods used in combination with automated
eligibility screening to identify clinical participants could also be employed to simplify
recruitment (Beauharnais et al., 2012; Pressler et al., 2012).
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Privacy concerns unique to human-associated microbial communities introduce another
challenge for microbiome research. For example, in the HMP, the identifier of the
sequencing machine generating each dataset was access--restricted, because this seemingly-innocuous information could be associated with a sequencing center and thus the location of
the donor individual (although de minimis risk guidelines have since been developed
(Rhodes et al., 2011)). Although consistency and streamlining of IRBs is an ongoing effort
in many fields, there is as yet little understanding of the subject protection ramifications of
releasing individual sets of host--associated microbial sequences. For many subjects enrolled
under earlier protocols, it is often possible to release only aggregate data, not detailed
clinical information that could theoretically be combined with ‘omics to allow the
identification of individual subjects. dbGAP, the protected--access database for sensitive
biomedical information (Mailman et al., 2007), plays an important role but can be
cumbersome to work with due to regulatory compliance and implementation complexity.
The generation of large, free, and open IRB--approved high--dimensional datasets will lead
to substantial advances across the board, both in the human microbiome and other areas of
modern genomic medicine.
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Human microbiome studies are not unique to any one NIH institute or center (IC), and they
are currently supported by over a dozen ICs. This diversity in research initiatives is exciting,
but cultural differences between ICs with respect to data sharing, accessibility and patient
confidentiality are a concern. A recently formed Trans--NIH Microbiome Working Group is
expected to be especially valuable in harmonized policy development between ICs, as well
as identifying opportunities to that broaden access to data and increase reusability of results.
Additional instruction to federal grant review committees on the interpretation and benefit of
‘omics approaches that complement traditional genetic approaches would also help advance
microbiome research, as would dedicated study sections with members that span the broad
range of expertise required to adequately assess such studies. Negotiating interoperability
within and across the NIH and other federal agencies will have a disproportionately large
and positive effect on microbiome research because it will eliminate the need for a large
number of pairwise negotiations on a case--by--case basis.

PROSPECTS FOR THE FUTURE
NIH-PA Author Manuscript

Despite all the challenges, there is immense potential for microbiome research. Significant
gains will be achieved with modest investments in training, improved submission tools,
increased metadata utilization, and resources such as standardized reagents, protocol
registries or reference datasets. Online tutorials with example data, webinars, virtual
machines and packaged software encapsulating data and methods for reproducibility, and
public computing environments such as the DIAG [http://diagcomputing.org] - which is
specifically designed for data-rich tasks such as those encountered in metagenomics - will
all play important roles. Experimental design guidelines, adequate power calculations, and
basic improvements to data submission tools are critical - yet very difficult to achieve in the
current funding climate - we must facilitate communication within the human microbiome
research community to overcome this. When we do, we will make it much easier for
investigators at all levels to enter the field, and to propagate standards and best practices
within the field.
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Thus while diverse microbial communities inhabit many locations of our bodies - and appear
to be associated with a spectrum of diseases - it will be the organization of our communities
of researchers and funding agency program managers that will ultimately improve human
health. Practically speaking, standardization at every level will enhance the application of
both top--down and bottom--up microbiome research. We believe that if the
recommendations we propose are implemented, the field will simultaneously be in a position
to make efficient use of existing resources, to consistently design, execute, and share new
study results, and to realize the full potential of improved outcomes for a broad range of
human diseases.
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